These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 22308584)

  • 1. [Secondary coronary heart disease prevention. Will CEPT inhibitors be the next breakthrough?].
    Einecke D
    MMW Fortschr Med; 2011 Dec; 153(49-50):17-8. PubMed ID: 22308584
    [No Abstract]   [Full Text] [Related]  

  • 2. Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis.
    Li C; Zhang W; Zhou F; Chen C; Zhou L; Li Y; Liu L; Pei F; Luo H; Hu Z; Cai J; Zeng C
    PLoS One; 2013; 8(10):e77049. PubMed ID: 24204732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
    Ballantyne CM; Shah S; Kher U; Hunter JA; Gill GG; Cressman MD; Ashraf TB; Johnson-Levonas AO; Mitchel YB
    Am J Cardiol; 2017 Feb; 119(3):388-396. PubMed ID: 27956003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future of cholesteryl ester transfer protein inhibitors.
    Rader DJ; deGoma EM
    Annu Rev Med; 2014; 65():385-403. PubMed ID: 24422575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [HDL and CETP in atherogenesis].
    Pöss J; Böhm M; Laufs U
    Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anacetrapib: a new weapon against dyslipidemia.
    Aperis G; Paliouras C; Tsampikaki E; Papakonstantinou N; Alivanis P
    Curr Clin Pharmacol; 2011 Nov; 6(4):227-35. PubMed ID: 22082322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients.
    Keene D; Price C; Shun-Shin MJ; Francis DP
    BMJ; 2014 Jul; 349():g4379. PubMed ID: 25038074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy and clinical trials.
    Elmallah W; Krasuski RA
    Curr Opin Lipidol; 2011 Dec; 22(6):512-3. PubMed ID: 22101564
    [No Abstract]   [Full Text] [Related]  

  • 9. Choice of lipid-regulating drugs.
    Med Lett Drugs Ther; 2001 May; 43(1105):43-8. PubMed ID: 11378632
    [No Abstract]   [Full Text] [Related]  

  • 10. Update on therapies targeting HDL: the mystery continues.
    Virani SS; Ballantyne CM
    Curr Opin Lipidol; 2011 Dec; 22(6):514-6. PubMed ID: 22101565
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of cholesteryl ester transfer protein inhibitor on vitamin E transport should be studied.
    Masterjohn C
    Am Heart J; 2009 Jul; 158(1):e11; author reply e13. PubMed ID: 19540377
    [No Abstract]   [Full Text] [Related]  

  • 12. Anacetrapib, a cholesteryl ester transfer protein inhibitor.
    Hooper AJ; Burnett JR
    Expert Opin Investig Drugs; 2012 Jan; 21(1):103-9. PubMed ID: 22191425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advancing therapy for hypercholesterolemia.
    Toutouzas K; Drakopoulou M; Skoumas I; Stefanadis C
    Expert Opin Pharmacother; 2010 Jul; 11(10):1659-72. PubMed ID: 20509773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid lowering in acute coronary syndromes: new evidence, new questions.
    Schwartz GG; Olsson AG
    Curr Atheroscler Rep; 2002 Jan; 4(1):1-3. PubMed ID: 11772415
    [No Abstract]   [Full Text] [Related]  

  • 15. Good news for 'good' cholesterol.
    Katsnelson A
    Nature; 2010 Nov; 468(7322):354. PubMed ID: 21085143
    [No Abstract]   [Full Text] [Related]  

  • 16. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme.
    Landmesser U; von Eckardstein A; Kastelein J; Deanfield J; Lüscher TF
    Eur Heart J; 2012 Jul; 33(14):1712-5. PubMed ID: 22696435
    [No Abstract]   [Full Text] [Related]  

  • 18. Niacin as a component of combination therapy for dyslipidemia.
    Miller M
    Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of anacetrapib in patients with or at high risk for coronary heart disease.
    Cannon CP; Shah S; Dansky HM; Davidson M; Brinton EA; Gotto AM; Stepanavage M; Liu SX; Gibbons P; Ashraf TB; Zafarino J; Mitchel Y; Barter P;
    N Engl J Med; 2010 Dec; 363(25):2406-15. PubMed ID: 21082868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prevention and treatment of coronary heart disease: lowering LDL, increasing HDL or monitoring both?].
    Windler E
    Internist (Berl); 1996 Jun; 37(6):643-6. PubMed ID: 8768000
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.